Skip to NavigationSkip to content

AZ asthma drug falls short in Phase 3 study

Published on 10/05/17 at 10:36am

AstraZeneca and its global biologics research and development arm MedImmune have announced that asthma treatment tralokinumab has failed to achieve its primary endpoint in its first Phase 3 trial.

Tralokinumab, an anti-interleukin-13 (IL-13) human monoclonal antibody, failed to show a clinically-significant ability to reduce annual asthma exacerbation rates compared to placebo across a large sample of patients with severe asthma during the Stratos 1 trial.

Around 315 million people suffer from asthma globally, with 10% of that number suffering from a severe form of the disease – the form which tralokinumab was engineered to treat. While the drug failed to adequately deliver, AZ is now waiting on the results of a second Phase 3 trial in the hope that it proves its efficacy. The second trial data is expected to become available in the later half of the year.

"Severe asthma is a heterogeneous disease with significant unmet needs and we will now await the Stratos 2 results in the second half of 2017 to explore the potential to treat a sub-group of uncontrolled asthma patients with tralokinumab," commented Executive Vice-President, Global Medicines Development and Chief Medical Officer Sean Bohen.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches